MotherToBaby has launched a new observational pregnancy study evaluating lebrikizumab-lbkz (Ebglyss; Eli Lilly and Company) in women with moderate to severe atopic dermatitis (AD)

Ebglyss (lebrikizumab-lbkz) - Eli Lilly

Aug 20, 2026